Evaluation Understanding TYK2 as a Therapeutic Target in the Management of Moderate to Severe Psoriasis Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). To what extent are you able to better achieve each of the following learning objectives? Describe the role of TYK2 in the pathophysiology and progression of PsO and associated implications for treatment 5 4 3 2 1 Evaluate the latest data on the efficacy, safety, dosing, and administration of novel TYK2 inhibitors for patients with PsO 5 4 3 2 1 Implement strategies to integrate TYK2 inhibitors and shared decision-making into the management of PsO 5 4 3 2 1 Please rate the faculty on the following: Jeffrey M. Cohen, MD: Knowledge, expertise, and teaching ability 5 4 3 2 1 Please rate the following components relating to this activity: Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Audience-participation portions (eg., Q&A, polling, pre/post-testing) 5 4 3 2 1 Resources and/or other materials supporting the activity 5 4 3 2 1 Overall 5 4 3 2 1 Therapeutic recommendations presented in this activity did not encourage inappropriate or excessive use of products/devices. Agree Disagree How many patients with Moderate to Severe Psoriasis do you see during a typical week? 0 patients 1-10 patients 11-20 patients 21-30 patients More than 30 patients Do you feel like there were any new data presented? Yes, please specify: No Did you learn anything new? Yes, please specify: No Did you gain confidence on the new information? Yes, why? No, why? Did this program include opportunities to learn as a part of a healthcare team? Yes, please specify: No Long-term maintenance data demonstrate durable clinical efficacy and a well-tolerated safety profile with 82.4% of patients achieving Psoriasis Area and Severity Index (PASI) 75 response at 2 years with which of the following? Brepocitinib Deucravacitinib Ropsacitinib Tivozanib A, C Which of the following statements regarding the inhibition of TYK2 signaling is TRUE? TYK2 inhibitors regulate signal transduction of receptors located downstream of IL-23 and IL-12 pathways targeting extracellular JAKs TYK2 inhibitors regulate signal transduction of receptors located downstream of IL-23 and IL-12 pathways and target intracellular JAKs TYK2 inhibitors regulate signal transduction of receptors located upstream of IL-23 and IL-12 pathways targeting extracellular JAKs TYK2 inhibitors regulate signal transduction of receptors located upstream of IL-23 and IL-12 pathways targeting intracellular JAKs How confident are you in your ability to optimally integrate TYK2 inhibitors into the management of plaque psoriasis? Very confident Confident Somewhat confident Not very confident Not at all confident Do you intend to make any additional changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No What challenges or barriers outside of your control may prevent you from changing your practice? Adverse effects of available treatments Affordability/cost Institutional policy Insurance/formulary Lack of patient education/engagement Limited resources/time Need more information on optimal management strategies Outdated or unclear guidelines Patient adherence Other: How might future activities help you address those barriers? 255 characters max The information presented in this activity did not serve to advance a proprietary interest of any commercial entity. Agree Disagree Based on my participation in this activity, I anticipate I will more often: (select all that apply) Select treatment for PsO based on patient characteristics, disease severity, and unmet needs associated with current standards of disease management Actively incorporate shared decision-making into strategies for the management of moderate-to-severe PsO Remain apprised of emerging data associated with the efficacy, safety, dosing, and administration of novel TYK2 inhibitors and their optimal role in clinical practice Consider TYK2 inhibitors for patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy Other (please specify): Previous
